US Stock MarketDetailed Quotes

TGTX TG Therapeutics

Watchlist
  • 41.400
  • +0.070+0.17%
Trading Apr 28 14:22 ET
6.50BMarket Cap276.00P/E (TTM)

About TG Therapeutics Company

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

Company Profile

SymbolTGTX
Company NameTG Therapeutics
Listing DateOct 7, 2005
Founded1993
CEOMr. Michael S. Weiss
MarketNASDAQ
Employees338
Fiscal Year Ends12-31
Address3020 Carrington Mill Boulevard,Suite 475
CityMorrisville
ProvinceNorth Carolina
CountryUnited States of America
Zip Code27560
Phone1-212-554-4484

Company Executives

  • Name
  • Position
  • Salary
  • Michael S. Weiss
  • Chairman of the Board, Chief Executive Officer and President
  • 15.84M
  • Sean A. Power
  • Chief Financial Officer, Treasurer and Corporate Secretary
  • 1.87M
  • Laurence N. Charney
  • Lead Independent Director
  • 304.70K
  • Kenneth Hoberman
  • Independent Director
  • 264.70K
  • Daniel Hume
  • Independent Director
  • 262.20K
  • Dr. Yann Echelard, PhD
  • Independent Director
  • 262.20K
  • Dr. Sagar Lonial, M.D.
  • Independent Director
  • 259.70K

Market Insights

Best Growth Stocks Best Growth Stocks

Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

Unlock Now

Discussing

Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context, Show More